Lynnet spearheaded Targazyme’s journey from concept to completing Phase 2 clinical trials, demonstrating enhanced survival and quality of life for cancer patients. This set the stage for Phase 3 trials and featured milestones like FDA Special Protocol Assessment, Orphan Drug Designations, and worldwide patents. Targazyme's technology garnered over $40 million in medical awards and formed key partnerships with companies like Astellas and Kyowa Hakko Kirin, alongside prestigious collaborations with MD Anderson Cancer Center. Lynnet’s career spans groundbreaking innovations, including the world's first caller ID at AT&T Bell Labs, pioneering wireless systems, and leading voice/video/data products at Cisco Systems, many achieving top market positions. Her leadership roles at Cisco, AT&T, and Qualcomm underline her knack for driving technological advancements to commercial success.